CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Ticagrelor With or Without Aspirin After Complex PCI Post-stenting fractional flow reserve vs coronary angiography for optimisation of percutaneous coronary intervention: TARGET-FFR trial Impact of bifurcation technique on 2-year clinical outcomes in 773 patients with distal unprotected left main coronary artery stenosis treated with drug-eluting stents When, where, and how to target vascular inflammation in the post-CANTOS era? Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic? Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study

Original Research

JOURNAL:CBSMD Article Link

Percutaneous Left Atrial Appendage Occlusion: How Much Do We Know?

CBSMD

Pre-reading

  • Definition of percutaneous left artrail appendage occlusion
  • Indications for LAAO therapy

  • How to define study endpoints, stroke and classifications, transient ischemic attack, cardiovascular mortality, non-cardiovascular mortality, procedural mortality, immediate procedural mortality, systemic embolism, pericardial effusion, bleeding events etc.  




RCTs


Year 2009, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial"

confirmed the efficacy of percutaneous closure of the LAA with this device was non-inferior to that of warfarin therapy. Although there was a higher rate of adverse safety events in the intervention group than in the control group, events in the intervention group were mainly a result of periprocedural complications. Closure of the LAA might provide an alternative strategy to chronic warfarin therapy for stroke prophylaxis in patients with non-valvular atrial fibrillation.